GGiantBullStocks

ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ · Healthcare

$6.44-8.00%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$748.75M
P/E ratio
EPS
Volume
2,932,953
52-week high
52-week low
Open
$7.00
Day high
$7.14
Day low
$6.42

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$84.28M-$171.3M-$1.74
2024$89.15M$8M$0.08
2023$30K-$54.37M-$0.57
2022$1.32M-$34.68M-$0.87
2021$5.51M-$20.24M-$0.70

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

CEO
Donn Casale
Employees
163
Country
US
IPO date
Dec 4, 2020

Similar stocks

Other Healthcare companies

Frequently asked questions

What is ARS Pharmaceuticals, Inc.'s stock price today?
SPRY is trading at $6.44 as of Jul 20, 2026.
What is ARS Pharmaceuticals, Inc.'s market cap?
ARS Pharmaceuticals, Inc. (SPRY) has a market capitalization of $748.75M.
Does ARS Pharmaceuticals, Inc. pay a dividend?
ARS Pharmaceuticals, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is ARS Pharmaceuticals, Inc. in?
ARS Pharmaceuticals, Inc. operates in the Healthcare sector.